With the ADA in full swing, virtually anyway, some key trends have emerged. First and this should be obvious by now CGM is the most transformative diabetes device ever. Second GLP-1 therapy continues to prove why usage is expanding. Both facts should be obvious to anyone whose been following diabetes devices and therapies but when ADA rolls around they are always reinforced with new data.
Now you wouldn’t think there is a digital diabetes connection to these two seemingly divergent facts but there is. All along we have been stating that digital diabetes is nothing more than old . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.